Key Takeaways JNJ has gained 17.7% in three months, adding nearly $63B in market cap.Innovative Medicine sales rose 2.4% despite Stelara's patent loss.MedTech sales grew 6.1%, boosted by Abiomed, Shockwave and new launches.Johnson & Johnson (JNJ) has delivered a strong run over the past three months, with shares up 17.7% and nearly $63 billion in market capitalization added. The stock’s technicals support this momentum. It has been trading consistently above its 50-day and 200-day moving averages since mid- ...